The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical models to predict response and survival in metastatic melanoma (MM) patients (pts) treated with anti-PD-1 alone (PD1) or combined with ipilimumab (IPI+PD1).
 
Ines Esteves Domingues Pires Da Silva
No Relationships to Disclose
 
Tasnia Ahmed
No Relationships to Disclose
 
Serigne Lo
No Relationships to Disclose
 
Rajat Rai
No Relationships to Disclose
 
Jessica Louise Smith
Honoraria - Bristol-Myers Squibb
 
John J. Park
No Relationships to Disclose
 
Caroline Nabhan
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Jennifer Leigh McQuade
No Relationships to Disclose
 
Douglas Buckner Johnson
Consulting or Advisory Role - Array Biopharma; Bristol-Myers Squibb; Incyte; Merck; Novartis
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy
Travel, Accommodations, Expenses - Genentech
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche